How a Cholesterol-Lowering Medication Could Reduce Heart Attack Risk
A recent study conducted at Cedars-Sinai Medical Center sheds light on how evolocumab, a drug that significantly lowers cholesterol, may help prevent heart attacks in individuals with coronary artery disease. Coronary artery disease occurs when cholesterol deposits accumulate along the walls of heart arteries, leading to the formation of plaques. These plaques often start as inflammatory regions, and as they grow, they become susceptible to rupture, potentially causing a heart attack.
Evolocumab belongs to a class of medications known as PCSK9 inhibitors, which are highly effective at reducing bad cholesterol levels in the blood. The study focused on patients with substantial noncalcified plaque buildup, a type of softer, more rupture-prone plaque considered at higher risk than calcified variants.
To assess the drug's impact, researchers utilized advanced imaging techniques such as positron emission tomography (PET) with radioactive sodium fluoride and coronary computed tomography angiography (CCTA), coupled with new artificial intelligence tools to measure inflammation and plaque volume. Patients received evolocumab, and after 18 months, scans revealed a significant reduction in inflammation and plaque size.
Dr. Daniel S. Berman, the study’s lead investigator, emphasized that beyond cholesterol reduction, evolocumab appears to lower arterial inflammation—a key factor in plaque instability. This inflammation decrease could be a crucial mechanism by which the drug reduces the risk of heart attacks.
The findings suggest that PCSK9 inhibitors like evolocumab not only control cholesterol levels but might also directly stabilize vulnerable plaques within the coronary arteries, providing a dual benefit in cardiovascular disease management.
This research advances our understanding of how targeted therapies can mitigate heart attack risk and highlights the importance of inflammation in coronary artery disease development. Further studies are ongoing to confirm and expand these results.
Source: https://medicalxpress.com/news/2025-05-cholesterol-drug-heart.html
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Early Cancer Treatment in Children Leads to Unanticipated Muscle Loss, Study Finds
New research reveals that children undergoing cancer treatment often lose skeletal muscle when they should be gaining it, leading to increased health risks and complicating recovery. Maintaining activity levels is vital for better outcomes.
Initiatives to Eliminate Race-Based Bias in Lung Function Testing
Efforts are intensifying to remove race-based adjustments from lung function testing, aiming for fairer and more accurate pulmonary assessments based on environmental and social factors. leading to updates in medical guidelines and disability evaluations.
Potential Cancer-Fighting Properties of Fermented Stevia Leaf Extract
Hiroshima University researchers discover that fermented stevia leaf extract selectively kills pancreatic cancer cells without harming healthy tissue, highlighting its potential as a natural anticancer agent.
Regular Exercise Outperforms GLP-1 Medication in Reducing Heart Attack and Stroke Risks Post-Weight Loss
Regular physical activity after weight loss offers greater cardiovascular protection than glp-1 medications, reducing inflammation and improving arterial health to lower heart attack and stroke risks.